RGEN News and Press, Repligen Corporation From 02/22/21

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.&#...

Medical supplier Repligen is set to report fourth quarter earnings on Feb. 24. Analysts expect EPS to grow by 55% and revenue to grow by 35.1%. The stock has been trending higher over the past 10 months with a trend channel forming. For further details see: Past Earnings...

Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday...

Repligen (RGEN) and protein engineering company Navigo Proteins announce that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.The resi...

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in n...

Regeneron (RGEN) is a leading biotechnology company; its science-driven approach has resulted in eight FDA-approved drugs and more than 20 product candidates in clinical development, explains Ingrid Hendershot, a lvalue-focused money manager and editor of Hendershot Investments. For further...

Similar to selling picks and shovels in the California gold rush, companies that make the tools and equipment for drug development can be great investments. Repligen (NASDAQ: RGEN) is a prime example. The company makes filtration, fluid management, and other bioprocessing tools that...

WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39th Annual J.P. Morgan Healthcare conference being held January 11-14.&#x...

Shares in bioprocessing technology company Repligen (NASDAQ: RGEN) rose by a whopping 107% in 2020, according to data provided by S&P Global Market Intelligence . Bioprocessing uses biological catalysts to produce a pharmaceutical, chemical, or food in a controlled envir...

WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proce...